Literature DB >> 32430351

Immune checkpoint inhibitor induced large vessel vasculitis.

Daisy Henderson1, Gelareh Eslamian2, Daniel Poon3, Simon Crabb4, Robert Jones5, Peter Sankey6, Bihani Kularatne7, Mark Linch8, Debra Josephs2.   

Abstract

This is a case report of a 67-year-old patient with castration resistant metastatic prostate cancer who developed an immune-mediated large vessel vasculitis following treatment with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cancer intervention; immunology; prostate cancer; unwanted effects / adverse reactions; vasculitis

Mesh：

Substances：

Year:  2020        PMID： 32430351      PMCID： PMC7239530          DOI： 10.1136/bcr-2019-233496

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  8 in total

1.  Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab.

Authors:  David R Minor; Stephen R Bunker; Judith Doyle
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

2.  Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4.

Authors:  Barbara L Goldstein; Lydia Gedmintas; Derrick J Todd
Journal:  Arthritis Rheumatol       Date:  2014-03       Impact factor: 10.995

3.  Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy.

Authors:  Ashish K Roy; Harshavardhan R Tathireddy; Moni Roy
Journal:  BMJ Case Rep       Date:  2017-09-23

4.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  J B A G Haanen; F Carbonnel; C Robert; K M Kerr; S Peters; J Larkin; K Jordan
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

5.  Vasculitis associated with immune checkpoint inhibitors-a systematic review.

Authors:  Anisha Daxini; Keri Cronin; Antoine G Sreih
Journal:  Clin Rheumatol       Date:  2018-06-19       Impact factor: 2.980

Review 6.  Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature.

Authors:  Laura C Cappelli; Anna Kristina Gutierrez; Clifton O Bingham; Ami A Shah
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-09-21       Impact factor: 4.794

7.  Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis.

Authors:  Hui Zhang; Ryu Watanabe; Gerald J Berry; Augusto Vaglio; Yaping Joyce Liao; Kenneth J Warrington; Jörg J Goronzy; Cornelia M Weyand
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-23       Impact factor: 11.205

8.  Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma.

Authors:  Joshua S Manusow; Leila Khoja; Nataly Pesin; Anthony M Joshua; Efrem D Mandelcorn
Journal:  J Immunother Cancer       Date:  2014-12-16       Impact factor: 13.751
  8 in total
  2 in total

Review 1.  Innate and Adaptive Immunity in Giant Cell Arteritis.

Authors:  Mitsuhiro Akiyama; Shozo Ohtsuki; Gerald J Berry; David H Liang; Jörg J Goronzy; Cornelia M Weyand
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

2.  Immune checkpoint molecule expression is altered in the skin and peripheral blood in vasculitis.

Authors:  Chie Miyabe; Yupeng Dong; Takaharu Ikeda; Kazuo Takahashi; Yoshishige Miyabe; Tamihiro Kawakami
Journal:  Sci Rep       Date:  2021-10-08       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.